A011000 Stock Overview
A biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
GeneOne Life Science, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩2,755.00 |
52 Week High | ₩4,735.00 |
52 Week Low | ₩1,996.00 |
Beta | -2.04 |
11 Month Change | -12.68% |
3 Month Change | 21.63% |
1 Year Change | -27.79% |
33 Year Change | -87.63% |
5 Year Change | 3.18% |
Change since IPO | 227.46% |
Recent News & Updates
Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31Why Investors Shouldn't Be Surprised By GeneOne Life Science, Inc.'s (KRX:011000) Low P/S
Jul 26Recent updates
Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31Why Investors Shouldn't Be Surprised By GeneOne Life Science, Inc.'s (KRX:011000) Low P/S
Jul 26Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?
Mar 20GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment
Jan 10Shareholder Returns
A011000 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -14.0% | 0.8% | -1.0% |
1Y | -27.8% | 39.0% | 1.0% |
Return vs Industry: A011000 underperformed the KR Biotechs industry which returned 34.8% over the past year.
Return vs Market: A011000 underperformed the KR Market which returned 0.6% over the past year.
Price Volatility
A011000 volatility | |
---|---|
A011000 Average Weekly Movement | 12.0% |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 6.5% |
10% most volatile stocks in KR Market | 12.2% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A011000's share price has been volatile over the past 3 months.
Volatility Over Time: A011000's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 73 | Young-Keun Park | www.genels.com |
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis.
GeneOne Life Science, Inc. Fundamentals Summary
A011000 fundamental statistics | |
---|---|
Market cap | ₩219.93b |
Earnings (TTM) | -₩73.64b |
Revenue (TTM) | ₩40.80b |
5.4x
P/S Ratio-3.0x
P/E RatioIs A011000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A011000 income statement (TTM) | |
---|---|
Revenue | ₩40.80b |
Cost of Revenue | ₩47.39b |
Gross Profit | -₩6.59b |
Other Expenses | ₩67.05b |
Earnings | -₩73.64b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -922.52 |
Gross Margin | -16.15% |
Net Profit Margin | -180.49% |
Debt/Equity Ratio | 13.0% |
How did A011000 perform over the long term?
See historical performance and comparison